A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Vismodegib

Registration Number: NCT01546519

Lead Sponsor: Genentech, Inc.

Brief Summary: This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and lymphoma) that are refractory to standard therapy or for whom no standard therapy exists.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 31

Inclusion Criteria

Histologically or cytologically confirmed advanced solid malignancy (including hepatocellular carcinoma and lymphoma) that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
Eastern Cooperative Oncology Group (ECOG) performance status </= 2 (Karnofsky >/=60%)
Acceptable bone marrow functions
Normal or varying degrees of renal or hepatic impairment according to NCI Organ Dysfunction Working Group criteria.
Organ function should be stable for at least 2 weeks before Day 1. In addition, there should be no evidence of acute exacerbation of hepatic/renal disease.
Patients with gliomas or known brain metastases who require corticosteroids or anticonvulsants must be on a stable dose of corticosteroids and seizure free for 1 month prior to enrollment. Patients with known brain metastases must be at least 4 weeks out from any radiation before starting the protocol (Day 1).
Documented negative serum pregnancy test for women of childbearing potential
For women of childbearing potential, agreement to the use of two acceptable methods of contraception during the study and for 7 months after discontinuation of vismodegib
For men with female partners of childbearing potential, agreement to use a latex, non-latex, or any other male condom and to advise their female partners to use an additional acceptable method of birth control during the study and for 2 months after discontinuation of study drug
Agreement not to donate blood/blood products during the study and for 7 months after discontinuing study drug
For men with normal renal and hepatic function, agreement to provide semen during the vismodegib treatment period for study assessment (optional), but otherwise NOT to donate semen during the vismodegib treatment period and for 2 months after discontinuation of study drug

Exclusion Criteria

Pregnancy or lactation
Chemotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Investigational agents within 28 days prior to study entry (Day 1)
Use of Pgp inhibitors within 7 days of Day 1
Use of gastric pH altering drugs except antacids within 7 days of Day 1
Major surgery within 14 days prior to treatment (Day 1). Patients with recent major surgery must have recovered from that surgery. Patients who are expected to have any major surgery during the study treatment period should not be enrolled.
Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of vismodegib or that might affect interpretation of the results from this study or renders the patient at high risk from treatment complications.
Severely impaired renal function (Cohort 2 only) should not have active hemolysis, and should not be on hemodialysis or peritoneal dialysis during the screening and study treatment period (Days 1-9).

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
5	Vismodegib	Severe hepatic impairment and normal renal function
1	Vismodegib	Control cohort with normal renal and normal hepatic function
2	Vismodegib	Severe renal impairment and normal hepatic function
3	Vismodegib	Mild hepatic impairment and normal renal function
4	Vismodegib	Moderate hepatic impairment and normal renal function

Primary Outcome Measures

Name	Time	Method
Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib	Day 1,2,4 and 0, 0.5, 1, 2, 4, 8 and 24 hours post dose on Day 8	Maximum observed plasma Concentration (Cmax) \& Concentration at steady-state (Css) following multiple doses of vismodegib (150 mg QD) were analyzed. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated. Blood samples for assessing Cmax and Css for analysis were collected following multiple oral doses of vismodegib at pre-dose and at 0.5, 1, 2, 4, 8 and 24 hours post-dose on Day 8. From the plasma concentration-time curve, the PK parameter Cmax and Css were determined by standard non-compartmental analysis using WinNonlin
The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib	Day 1, 2, 4 and 0, 0.5, 1, 2, 4, 8 and 24 hours postdose on Day 8	The steady state pharmacokinetic profile following oral administration of multiple doses of vismodegib included determining the area under the curve over the dosing interval (AUC\[0-24 hours\]). The AUC\[0-24 hrs\]) was determined by standard non-compartmental analysis using WinNonlin. Blood samples were collected at pre-dose and at 0.5, 1, 2, 4, 8 and 24 hours post-dose on Day 8 to estimate AUC(0-24 hrs).

Secondary Outcome Measures

Name	Time	Method
Amount of Vismodegib Excreted Into Urine in 24 Hours (Ae0-24hr)	24 hr total interval on Day 8	The amount of total vismodegib excreted in urine over a 24-hr total interval (Ae0-24hr) was estimated.
The Percentage of Dose of Vismodegib in 24-hour Total Urine	24 hr total interval on Day 8	The percentage of dose vismodegib excreted in urine over a 24-hr total interval was estimated
Minimum Plasma Concentration (Cmin) of Vismodegib	Up to 8 days	Cmin is defined as the minimum observed plasma concentration of Vismodegib. This was a pre-specified PK parameter. However, due to minimal fluctuation of Vismodegib concentrations at steady state, this parameter could not be determined.
Renal Clearance of Vismodegib	0, 0.5, 1, 2, 4, 8 and 24 hours postdose on Day 8	Renal clearance (CLR) is defined as the apparent total clearance of the drug from plasma after oral administration.
Time to Maximum Plasma Concentration (Tmax) of Vismodegib	Up to 8 days	Tmax is the time to reach maximum plasma concentration of vismodegib. This was a pre-specified PK parameter. However, due to minimal fluctuation of Vismodegib concentrations at steady state, this parameter could not be determined.
Apparent Clearance (CL/F) of Vismodegib	Up to 8 days	CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr). This was a pre-specified PK parameter. However, due to minimal fluctuation of vismodegib concentrations at steady state, this parameter could not be determined.
Apparent Non-renal Clearance (CLNR/F) of Vismodegib	Up to 8 days	Apparent Non-Renal Clearance (CLNR) describes the removal of vismodegib by organs other than the kidneys. This was a pre-specified PK parameter. However, due to minimal fluctuation of vismodegib concentrations at steady state, this parameter could not be determined.